Sunshine Biopharma (NASDAQ:SBFM) Stock Price Down 0.8% – What’s Next?

Shares of Sunshine Biopharma, Inc. (NASDAQ:SBFM) fell 0.8% during trading on Thursday . The company traded as low as $1.1750 and last traded at $1.18. 36,007 shares changed hands during mid-day trading, a decline of 2% from the average session volume of 36,839 shares. The stock had previously closed at $1.19.

Analyst Ratings Changes

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of Sunshine Biopharma in a report on Thursday, January 22nd. One investment analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, Sunshine Biopharma currently has a consensus rating of “Hold” and a consensus price target of $7.00.

Sunshine Biopharma Stock Down 0.8%

The firm has a market cap of $5.79 million, a P/E ratio of -1.16 and a beta of 1.53. The business has a fifty day moving average of $1.29 and a 200 day moving average of $1.47.

Sunshine Biopharma (NASDAQ:SBFM) last issued its earnings results on Thursday, November 13th. The company reported ($0.19) EPS for the quarter, missing the consensus estimate of ($0.13) by ($0.06). Sunshine Biopharma had a negative return on equity of 24.96% and a negative net margin of 16.06%.The business had revenue of $9.42 million for the quarter, compared to the consensus estimate of $11.10 million.

Institutional Trading of Sunshine Biopharma

An institutional investor recently bought a new position in Sunshine Biopharma stock. Two Sigma Investments LP purchased a new stake in Sunshine Biopharma, Inc. (NASDAQ:SBFM) during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor purchased 21,399 shares of the company’s stock, valued at approximately $32,000. Two Sigma Investments LP owned about 0.44% of Sunshine Biopharma as of its most recent filing with the Securities and Exchange Commission. Institutional investors and hedge funds own 41.98% of the company’s stock.

Sunshine Biopharma Company Profile

Sunshine Biopharma, Inc is a biotechnology company focused on the research, development and commercialization of novel drug candidates primarily for oncology. The company specializes in small-molecule therapeutics designed to overcome multidrug resistance and to target hard-to-treat cancers. Its preclinical pipeline emphasizes compounds that intercalate DNA and inhibit topoisomerase II, with the goal of advancing candidates into clinical trials for various solid tumors.

Among its lead programs, Sunshine Biopharma is advancing anthracycline-based compounds, including Bisantrene, which has demonstrated activity against breast and prostate cancer cell lines, and Adva-27a, a novel analog being evaluated for glioblastoma multiforme and other drug-resistant malignancies.